A Phase 1/2a Dose Escalation Study of AST-OPC1 in Subjects With Subacute Cervical Spinal Cord Injury

Trial Profile

A Phase 1/2a Dose Escalation Study of AST-OPC1 in Subjects With Subacute Cervical Spinal Cord Injury

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Sep 2018

At a glance

  • Drugs OPC 1 (Primary)
  • Indications Spinal cord injuries
  • Focus Adverse reactions; Proof of concept
  • Acronyms SCi-STAR; SCiSTAR
  • Sponsors Asterias Biotherapeutics
  • Most Recent Events

    • 12 Sep 2018 Additional data results (Cohort 2; 24-months) presented in an Asterias Biotherapeutics media release.
    • 31 Jul 2018 Updated results from the 25 subjects (SCiStar study) and 5 subjects from Phase 1 safety study (245419) are presented in an Asterias Biotherapeutics media release.
    • 31 Jul 2018 According to an Asterias Biotherapeutics media release, the company expects to publish the 12 months data for the entire study in the first quarter of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top